Articles

Published on 22 October 2014

2013/3 GaBI Journal Table of Contents

Contents Editor's Letter Latest features in GaBI Journal, 2013, Issue 3 Editorial Italy’s final position paper on biosimilars and new price and reimbursement pathway Commentary Commentary on the recommendations of...

3.032 views

Read more →

Original Research

Published on 24 November 2022

Pharmacokinetic bioequivalence of sitagliptin phosphate tablet formulations: a randomized, open-label, crossover study in healthy volunteers

Author byline as per print journal: Chuei Wuei Leong1, PhD; Elton Sagim1, BBiomedSc; Kar Ming Yee1, BPharm; Muhammad Shalhadi Saharuddin1, BSc; Nik Mohd Zulhakimi Nik Abdullah1, BSc; Noramirah Farhanah Saberi1,...

bioequivalence, new branded generics, pharmacokinetics, sitagliptin

DOI: 10.5639/gabij.2023.1201.003

3.023 views

Read more →

Editor's Letter

Published on 10 January 2018

Editor’s introduction to the initial issue of the seventh volume of GaBI Journal

There are many frustrating differences between reality and what is possible in every aspect of life, including politics, economics, science and health. This issue begins with a Commentary by Adjunct...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2018.0701.001

3.014 views

Read more →

Editor's Letter

Published on 20 May 2021

What to look forward to in GaBI Journal, 2021, Issue 2

The current pandemic has greatly amplified the already existing disparities in access to health care. Many countries are facing a lack of access to or funding to pay for the...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2021.1002.005

2.995 views

Read more →

Published on 05 January 2016

2015/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2015, Issue 3 Editorial Advances in analytical characterization of biosimilars Letters to the Editor Access to safe and effective biopharmaceuticals Commentary The...

2.994 views

Read more →

Editor's Letter

Published on 15 December 2017

Fourth and final issue of GaBI Journal’s sixth volume

Change is inevitable but often resisted, including or even especially in medicine. Hand washing is still neglected 170 years after Semmelweis’ work, misuse of antibiotics persists 72 years after Fleming...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2017.0604.030

2.994 views

Read more →

Published on 22 October 2014

2013/4 GaBI Journal Table of Contents

Contents Editor's Letter GaBI Journal publishes four issues in 2013 Editorial Suggested evaluation of biological drugs role for WHO – Editor’s response Do low- to middle-income countries need a biosimilar...

2.974 views

Read more →

Published on 01 January 2018

2017/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s sixth volume Letters to the Editor Clear naming, traceability of biological medicines will protect patients Comment on the non-biological complex...

2.965 views

Read more →

Published on 04 January 2017

2016/4 GaBI Journal Table of Contents

Contents Editor’s Letter Fourth and final issue of GaBI Journal’s fifth volume Editorial Physicians, Hippocrates and biosimilars: applying ancient principles in a modern society Original Research Naming and labelling of...

2.927 views

Read more →

Published on 07 July 2016

2016/2 GaBI Journal Table of Contents

Contents Editor’s Letter What to look forward to in GaBI Journal, 2016, Issue 2 Editorial Adjusted indirect comparisons between generics – bioequivalence and interchangeability Review Article Assessment of the interchangeability...

2.899 views

Read more →

Published on 08 June 2016

2016/1 GaBI Journal Table of Contents

Contents Editor’s Letter Editor’s introduction to the initial issue of the fifth volume of GaBI Journal Letters to the Editor First biosimilar of infliximab approved in Brazil: response from the...

2.840 views

Read more →

Editor's Letter

Published on 28 January 2019

Fourth and final issue of GaBI Journal’s seventh volume

Globalization of the world’s economy has clearly created both major advances and ongoing challenges including in the pharmaceutical industry. Naming of pharmaceuticals might seem to be an uninteresting topic to...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2018.0704.028

2.811 views

Read more →